{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"10.0","upperLimit":"56.1","value":"48.1"},{"groupId":"OG001","lowerLimit":"1.2","upperLimit":"17.4","value":"4.6"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"14"},{"groupId":"OG001","value":"12"}],"units":"Participants"}],"description":"Defined as time (in months) from the first day that all criteria were met for CCyR until the date of progression (based on the Investigator's assessment) or death (for participants whose best response was CCyR). CCyR = 0% Ph+ metaphases of ≥ 20 analyzed metaphases in BM aspiration. The Kaplan-Meier plot was used. A 2-sided, 95% CI for the median was computed using the Brookmeyer and Crowley method.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with imatinib-resistant Philadelphia chromosome positive (Ph+) chronic myeloid leukemia (CML) in chronic phase (CP). Starting Dose Level of 60 mg/m\\^2; Escalated/Dose level 2 of 80 mg/m\\^2. QD, as long as clinical benefit was maintained.","id":"OG000","title":"Stratum1 Ph+ CP-CML; Dasatinib 60 mg/m^2 Starting Dose"},{"description":"Participants with imatinib-resistant or imatinib-intolerant Ph+ CML in accelerated phase (AP), or in myeloid blast phase (MBP), or in lymphoid blast phase (LBP); or relapsed or refractory Ph+ acute lymphoblastic leukemia (ALL) after imatinib use; or second or subsequent relapse of Ph+ acute myeloid leukemia (AML). Starting Dose Level of 60 mg/m\\^2; Escalated/Dose level 2 of 80 mg/m\\^2. QD, as long as clinical benefit was maintained.","id":"OG001","title":"Stratum2/3 Ph+ALL or AP/BP-CML;Dasatinib60mg/m^2 Starting Dose"}],"paramType":"MEDIAN","populationDescription":"All treated participants who had cytogenetic response. Participants with at least 1 metaphase observed \\& the number of Ph+ metaphases smaller than the total number of metaphases \\[%Ph+ \\<100%\\]) were considered responders. Participants who neither progressed nor died were censored on the date of their last valid cytogenetic assessment.","reportingStatus":"POSTED","timeFrame":"From the date of first CCyR assessment to date of progression, death, or last tumor assessment (maximum participant duration of response of 45.1 months)","title":"Duration of Complete Cytogenetic Response (CCyR) in Responders: Stratum 1 [Ph+ CP-CML] and Stratum 2/3 [Ph+ ALL or AP/BP-CML]","type":"SECONDARY","unitOfMeasure":"months"}